Bristol Myers Squibb Company $BMY Holdings Raised by Principal Financial Group Inc.

Key Points

• Principal Financial Group increased its Bristol Myers Squibb stake by 9.8% in the second quarter, adding 227,527 shares to own 2.55 million shares valued at approximately $146.9 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company also maintained a $0.63 quarterly dividend, representing a 3.9% yield.
• Analyst sentiment remains moderately positive, with a consensus price target of $66.06, while recent developments include FDA approval for ZENBEXUS and ongoing pipeline expansion. However, a revived $6.7 billion lawsuit introduces potential financial and legal risks.

Principal Financial Group Inc. raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,549,445 shares of the biopharmaceutical company's stock after buying an additional 227,527 shares during the period. Principal Financial Group Inc. owned about 0.12% of Bristol Myers Squibb worth $146,899,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Journey Advisory Group LLC increased its stake in shares of Bristol Myers Squibb by 1.2% in the second quarter. Journey Advisory Group LLC now owns 17,141 shares of the biopharmaceutical company's stock worth $988,000 after acquiring an additional 200 shares during the last quarter. TD Asset Management Inc boosted its position in Bristol Myers Squibb by 51.4% during the second quarter. TD Asset Management Inc now owns 2,007,448 shares of the biopharmaceutical company's stock valued at $115,669,000 after purchasing an additional 681,472 shares during the last quarter. SmartHarvest Portfolios LLC grew its stake in Bristol Myers Squibb by 83.1% in the second quarter. SmartHarvest Portfolios LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $348,000 after purchasing an additional 2,741 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in Bristol Myers Squibb in the second quarter valued at about $84,000. Finally, Ascent Group LLC increased its position in Bristol Myers Squibb by 46.4% in the 2nd quarter. Ascent Group LLC now owns 55,716 shares of the biopharmaceutical company's stock worth $3,210,000 after purchasing an additional 17,649 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $63.86 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a fifty day simple moving average of $59.56 and a 200 day simple moving average of $58.97. The company has a market cap of $130.45 billion, a P/E ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The business's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BMY shares. Citigroup reiterated a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. UBS Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 5th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued an "overweight" rating for the company. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source